Hebei Medical University Fourth Hospital
171
51
59
17
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 60/100
2.9%
5 terminated/withdrawn out of 171 trials
77.3%
-9.3% vs industry average
13%
23 trials in Phase 3/4
6%
1 of 17 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (171)
Neoadjuvant Sacituzumab Tirumotecan Plus Toripalimab in Locally Advanced Esophageal Squamous Cell Carcinoma
Role: lead
Apatinib With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2- Advanced Breast Cancer
Role: collaborator
Efficacy and Safety of Serplulimab Combined With Chemotherapy as Neoadjuvant Treatment for Locally Advanced Gastric Cancer or Adenocarcinoma of Esophagogastric Junction
Role: collaborator
Paclitaxel Polymeric Micelles and Cisplatin Plus Sintilimab as Neoadjuvant Therapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
Role: lead
QL1706 Plus Neoadjuvant Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer With a Poor Response to Neoadjuvant Chemotherapy
Role: lead
SABR Combined With Axitinib and Toripalimab for Oligometastatic Renal Cell Carcinoma
Role: lead
Radiotherapy + Systemic Therapy as Conversion Therapy for pMMR/MSS T4M0 Colon Cancer（Neo-Color）
Role: lead
Neoadjuvant Chemoradiation With Nal-IRI and Capecitabine Guided by UGT1A1 Status in Patients With Rectal Cancer
Role: lead
Tumor Local Excision +Postoperative Adjuvant Chemoradiotherapy for T1-2N0M0 Low/Ultra-Low Rectal Cancer
Role: lead
Radiotherapy Combined With QL1706 and Bevacizumab for Unresectable Non-metastatic Hepatocellular Carcinoma
Role: lead
Involved-field Radiotherapy-TNT Combined With PD-1 Inhibitor for pMMR Locally Advanced Rectal Cancer (Neo-Field I)
Role: lead
Short-course Radiotherapy in TNT Combined With Enlonstobart for pMMR LARC
Role: lead
PregnAncy-Related Aortic DISsEction in China
Role: collaborator
Becotatug Vedotin Plus Cisplatin and Radiotherapy in LA-ESCC
Role: lead
Surgery vs. No Surgery for Primary Tumor in De Novo Stage IV Breast Cancer With Solitary Bone Metastases
Role: collaborator
Hypofractionated Radiotherapy +Chemotherapy+ Camrelizumab as Neoadjuvant Therapy for Pancreatic Cancer
Role: lead
Sedation in ICU Patients With Mechanical Ventilation
Role: collaborator
SBRT Plus QL1706 as Second-Line Therapy for Hepatocellular Carcinoma
Role: lead
Cardiac Safety Management and Immune Microenvironment Changes After Thoracic Radiotherapy: A Prospective Observational Study
Role: lead
Postoperative Hypoxemia Increases the Risk of Anastomotic Leak After Radical Esophagectomy
Role: collaborator